United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - pamidronate disodium - solution for infusion - 15mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - pamidronate disodium - solution for infusion - 6mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - pamidronate disodium - solution for infusion - 15mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - pamidronate disodium - solution for infusion - 9mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - pamidronate disodium - solution for infusion - 15mg/1ml

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع البتراء للمواد الطبية - petra drug store - pamidronate disodium 9 mg/ml - 9 mg/ml

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - risedronate sodium (unii: ofg5exg60l) (risedronic acid - unii:km2z91756z) - risedronate sodium 5 mg - risedronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women. in postmenopausal women with osteoporosis, risedronate reduces the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see clinical studies (14.1, 14.2) ]. risedronate sodium tablets are indicated for treatment to increase bone mass in men with osteoporosis. risedronate sodium tablets are indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment (daily dosage of greater than or equal to 7.5 mg of prednisone or equivalent) for chronic diseases. patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin d. risedronate sodium tablets are indicated for treatment of paget’s disease of bone in men and women. the optimal duration of use has not been determined. the safety and effectiveness of risedronate

Ireland - English - HPRA (Health Products Regulatory Authority)

neomed technology ltd - pamidronate disodium - concentrate for soln for inf - 3mg/ml mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

neomed technology ltd - pamidronate disodium - concentrate for soln for inf - 9mg/ml mg/ml

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - disodium pamidronate 3 mg/ml - eq. pamidronic acid 2,527 mg/ml - concentrate for solution for infusion - 3 mg/ml - pamidronate disodium 3 mg/ml - pamidronic acid